CN107537023A - A kind of laminin surface of a wound maintenance agent - Google Patents
A kind of laminin surface of a wound maintenance agent Download PDFInfo
- Publication number
- CN107537023A CN107537023A CN201610472087.1A CN201610472087A CN107537023A CN 107537023 A CN107537023 A CN 107537023A CN 201610472087 A CN201610472087 A CN 201610472087A CN 107537023 A CN107537023 A CN 107537023A
- Authority
- CN
- China
- Prior art keywords
- laminin
- parts
- wound
- bactericide
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
A kind of laminin surface of a wound maintenance agent is using animal blood plasma laminin sediment as main component, is formed added with sterile saline and pharmaceutic adjuvant.Its specific Parts by Ingredients, which matches, is：1 30 parts of animal blood plasma laminin sediment, 1 20 parts of NMF, 0.01 3.0 parts of bactericide, sterile saline complements to 100 parts；The bactericide is chlorine dioxide or chlorine dioxide precursor；Described NMF is medical glycerine or vegetable oil.The present invention can be made into three kinds of formulations：Aqua, pulvis, paste, preparation technology is simple, is adapted to large-scale production.NMF and bactericide are with the addition of in product, glycerine or vegetable oil have moisturizing and the bioactivity to LN has certain protective effect, and bactericide can strengthen antibacterial effect, avoid wound courses of infection.Product of the present invention can directly spray, be applied to the wound of the patients such as the rotten foot of burn, wound, diabetes, bedsore and other chronic ulcer of skin, easy to use, good effect.
Description
Technical field
The present invention relates to biomedicine field, more particularly to a kind of laminin surface of a wound maintenance agent.
Background technology
Laminin (laminin, LN) is also known as flaggy element, and its molecular weight is 820kDa, the sugar containing 13-15%, there is three
Individual subunit, i.e. heavy chain (α chains, 400kDa) and β 1 (215kDa), β 2 (205kDa) two light chains.Presented in structure asymmetric
Cross, long-armed and three similar galianconism are formed by one, this four arms have bar-shaped section and spherical end domain.The Hes of β 1
There are two globular domains on the galianconism of β 2, the galianconism on α chains there are three globular domains, wherein having a domain with IV type glue
Original combines, second same Heparin-binding of domain, the domain also combined with cell surface receptor.LN is to form cytoplasm
A kind of non-collagen glycoprotein, mainly synthesized in liver by endothelial cell and fat-storing cell, basilar memebrane formed together with collagen
Composition, mainly produced by epithelial cell and endothelial cell, be to occur earliest extracellular matrix components in embryonic development.
In body vital movement, LN biological functions are the media that cell is adhered to matrix, and with a variety of basement membrane componentses
With reference to adjusting cell growth and differentiation, also assist in the numerous pathologic processes of body.It mainly serves following：LN may be by huge
The cell components such as phagocyte, lymphocyte discharge growth factor, promote fibroblast proliferation and synthesis collagenous fibres, aggravate fine
Dimensionization lesion degree, LN participate in the overall process of fibrosis.LN plays key as assembling of the principal structural component to basement membrane of basement membrane
Effect, form network structure in cell surface and cell is fixed on basement membrane；LN plays key in the migration of primordial germ cells
Effect；In the adhesion of cell development process moderate stimulation cell, cell movement；LN can also stimulate the growth of the neuraxis in embryo, and
Live again long after promoting the neurotrosis of adults and regenerate；Such as FTN, extracellular LN can influence cell
Growth, migration and differentiation.Substantial amounts of studies and clinical application it was demonstrated that LN played in the reparation and healing of wound it is particularly significant
Effect, to having significant effect in the healing therapy of Hard agglut wound, be promote it is refractory close the surface of a wound key substance.
Pharmaceutically acceptable excipient includes but is not limited to, such as aluminum oxide, aluminum stearate, buffer (such as phosphate), sweet ammonia
Acid, ion-exchanger (for example to help the controlled release of charged species), lecithin, the partial glyceride of saturated vegetable fatty acid
Mixture, potassium sorbate, haemocyanin (such as human serum albumins), sorbic acid, water, salt or electrolyte are for example based on cellulose
Material, cataloid, disodium hydrogen phosphate, magnesium trisilicate, polyacrylate, PAG such as polyethylene glycol,
Polyethylene-polyoxypropylene block polymer, polyvinylpyrrolidone, potassium hydrogen phosphate, protamine sulfate, 1 race's halide salts example
Such as sodium chloride, sodium carboxymethylcellulose, wax, lanolin and zinc salt.Liposomal suspensions, which can also be applied, makees pharmaceutical acceptable carrier.
Injectable solution or suspension can use suitable nontoxicity, the available diluent of parenteral or solvent to be matched somebody with somebody
System, such as 1,3-BDO, isotonic sodium chloride solution, mannitol, woods grignard (Ringer ' s) solution, saline solution or water；
Or scattered or wetting and the suspending agent being adapted to, such as sterile, gentle, fixed oil, including the monoglyceride of synthesis or
Dialycerides, and aliphatic acid, including oleic acid；Naturally occurring vegetable oil such as coconut oil, cottonseed oil, peanut oil, sesame oil
Deng；Glycerine；Polyethylene glycol；Propane diols；Or other synthetics；Antimicrobial such as phenmethylol and p-hydroxy Benzoic Acid first
Ester；Antioxidant such as ascorbic acid and sodium hydrogensulfite；Buffer such as acetate, citrate and phosphate；Chelating agent
Such as ethylenediamine tetra-acetic acid (EDTA)；For adjusting tension medicament such as sodium chloride and dextrose；And combinations thereof.Parenteral
Preparation can be encapsulated in by ampoule, disposable syringe or multiple dose vials made of glass, plastics or other suitable materials.
Buffer, preservative, antioxidant etc. can be mixed as needed.When intravenous apply, suitable carrier includes physiology salt
Water, phosphate buffered saline (PBS), and containing thickener and cosolvent such as glucose, polyethylene glycol, polypropylene glycol and its mix
The solution of compound.Liposomal suspensions, including tissue targeted liposome, can also be suitable as pharmaceutical acceptable carrier.
Laminin (laminin, LN) laminin is primarily present in basement membrane (basal lamina) structure, is
Non- collagen glycoprotein specific to basement membrane, relative molecular mass are exactly that these independent binding sites make LN as a bridge point
Son, mediated cell combine with basement membrane.
" laminin " refers to any one for generally participating in the glycoprotein family of formation and the maintenance of extracellular matrix.
Laminin is the heterotrimer formed by α chains, β chains and γ chains.The various chains of specific laminin can influence point
The property of son.In the disclosure in some cases, fragment, the derivative or similar of various different laminins can be used
Thing, for example, at least a part and at least substantially homologous laminin of the chains of laminin α 1.
Serum LN levels are often parallel in IV Collagen Type VIs, HA etc., there is weight in terms of liver fibrosis especially portal hypertension diagnosis
It is worth.It has further been found that LN is relevant with tumor invasion and metastasis, diabetes etc..
So LN major function is exactly to be played a crucial role as assembling of the principal structural component to basement membrane of basement membrane, thin
Cellular surface forms network structure and cell is fixed on basement membrane.
LN also has many other effects, such as in the adhesion of cell development process moderate stimulation cell, cell movement.LN can also
The growth of the neuraxis in embryo is stimulated, and lives again long after promoting the neurotrosis of adults and regenerates.Such as FTN,
Extracellular LN can influence the growth, migration and differentiation of cell.LN plays a crucial role in the migration of primordial germ cells.
LN is also a kind of large-scale glycoprotein, and basement membrane is formed together with IV Collagen Type VIs, is occurred earliest in embryonic development
Extracellular matrix components.
Laminin is primarily present in basement membrane (basal lamina) structure, is non-collagen sugar egg specific to basement membrane
In vain, relative molecular mass 820kDa, the sugar containing 13-15%, there are three subunits, i.e. heavy chain (α chains, 400kDa) and β 1
(215kDa), β 2 (205kDa) two light chains.Asymmetric cross is presented in structure, it is long-armed and three are similar short by one
Arm is formed.This four arms have bar-shaped section and spherical end domain.There are two globular domains on β 1 and the galianconism of β 2, on α chains
Galianconism have three globular domains, wherein have a domain with IV Collagen Type VIs combine, second same Heparin-binding of domain,
The domain also combined with cell surface receptor.Exactly these independent binding sites make LN be situated between as a bridge molecule
Guided cell combines with basement membrane.So LN major function is exactly to play key as assembling of the principal structural component to basement membrane of basement membrane
Effect, form network structure in cell surface and cell is fixed on basement membrane.
LN also has many other effects, such as in the adhesion of cell development process moderate stimulation cell, cell movement.LN can also
The growth of the neuraxis in embryo is stimulated, and lives again long after promoting the neurotrosis of adults and regenerates.Such as FTN,
Extracellular LN can influence the growth, migration and differentiation of cell.LN plays a crucial role in the migration of primordial germ cells.
LN is also a kind of large-scale glycoprotein, and basement membrane is formed together with IV Collagen Type VIs, is occurred earliest in embryonic development
Extracellular matrix components.LN molecules are formed by a heavy chain (α) and two light chains (β, γ) by means of disulfide bond crosslinking, and profile is in cross
Shape, three galianconism are respectively by the N-terminal Sequence composition of three peptide chains.Each galianconism includes two Ge Qiu areas and two quarter butt areas, long-armed
It is made up of bar area and ball area.
In early days, researcher studies it in burn, wound, congenital muscular dystrophy infection using human plasma extraction LN
Etc. application, achieve significant curative effect, but because people's blood resource lacks, expensive and mankind's blood relationship infectious disease agent is not
The reason such as easy to control, is very restricted the development and application of LN products.Animal blood is started with recent years carries out LN preparations,
But so far still in laboratory extraction, theoretical research stage, so far there are no being used as functional component using laminin (LN)
Maintenance agent Related product listing applied to burn, wound.
In various different embodiments, present disclose provides treatment DMD, strengthens muscle after impaired or damage
Repair, or the method for reducing the seriousness of muscle damage or damage.Other embodiments provide the side of enhancing wound healing
Method.Laminin is considered as breeding and be divided into new muscle cell and myotube by activating satellite cell to help muscle
Regeneration.Therefore, compared with the native state of object, muscle reparation can be strengthened.
In other embodiments, present disclose provides the method for promoting anathrepsis.Anathrepsis can be beneficial
In other PATIENT POPULATIONs that such as the elderly or muscle repair ability reduce, or simply accelerate the undamaged patient of original physiology
Muscle repair process.In a particular embodiment, using laminin can sportsman or other have activity induce
Muscle damage or damage people in help muscle reparation, or reduce muscle damage.In other implementations, with for example by anticipating
In the patient of muscle damage caused by outer or impaired, muscle reparation can be increased by applying laminin
The content of the invention
It is an object of the invention to provide a kind of bioavilability is higher, curative effect is stablized, have no side effect, medication is convenient, profit
In the laminin surface of a wound maintenance agent of production, the maintenance agent can strengthen cell or tissue reparation, regeneration or maintenance, can accelerate
The healing of the wounds such as patient's burn, wound, ulcer.
Based on above-mentioned purpose, the present invention adopts the following technical scheme that：
The laminin surface of a wound maintenance agent of the present invention is using animal blood plasma laminin sediment as main component, is added
It is made up of sterile saline and pharmaceutic adjuvant.Its specific Parts by Ingredients, which matches, is：Animal blood plasma laminin precipitates
Thing 1-30 parts, NMF 1-20 parts, bactericide 0.01-3.0 parts, sterile saline, complement to 100 parts.
Wherein, the bactericide is chlorine dioxide or chlorine dioxide precursor, and wherein chlorine dioxide precursor is sodium chlorite, Asia
One or more in potassium chlorate, lithium chlorite, magnesium chlorite, barium chlorite；Emollient is medical glycerine or vegetable oil.
Wherein, described NMF is in the vegetable oil such as medical glycerine or coconut oil, cottonseed oil, peanut oil, sesame oil
It is a kind of.
The major function and purposes of product of the present invention are as follows：
(1) LN may discharge growth factor by cell components such as macrophage, lymphocytes, promote fibroblast to increase
Grow and synthesize collagenous fibres, good extracellular environment is provided for the reparation of wound.
(2) LN is played a crucial role as assembling of the principal structural component to basement membrane of basement membrane, and network is formed in cell surface
Cell is simultaneously fixed on basement membrane by structure, stimulate cell to adhere in wound, cell movement, the migration of epithelial cell and propagation with
Wound is repaired, accelerating wound healing, mitigates healing scar.
(3) auxiliary material glycerine or other plant oil can keep wound moist in product, prevent dry and cracked, moistening skin beautifying, while right
LN bioactivity has certain protective effect.
(4) antibacterial effect can be strengthened by bactericide being added in this product, avoid wound infection.The present invention can be made into three kinds of agent
Type：Aqua, pulvis, paste.Due to LN molecules, conservative is very strong during evolution, and the FN in various liquids of animals has non-
Often similar structure, property and biological function, the FN of separate sources can be substituted for each other use.Laminin wound of the present invention
Face maintenance agent is using animal blood plasma LN as primary raw material, and antibacterial effect can be strengthened by adding NMF and bactericide, avoid wound sense
Dye, glycerine or vegetable oil has moisturizing and the bioactivity to LN has certain protective effect.Product of the present invention can directly spray, apply
In the wound of the patients such as burn, wound, the rotten foot of diabetes, bedsore and other chronic ulcer of skin.
Embodiment
With reference to specific embodiment, the present invention is further illustrated.
Embodiment 1：
For the paste formulation of the present invention
1st, 30 parts of animal blood plasma laminin sediment, 10 parts of NMF, 3.0 parts of bactericide, stirring make emulsification uniform,
Cream or ointment is made.
2nd, by specification requirement potting in aseptic plastic bottle, as laminin surface of a wound maintenance agent product.
Embodiment 2：
For the aqua formulation of the present invention
1st, by through examining 2 parts of 10 parts qualified of animal blood plasma laminin sediment, 0.5 part of bactericide and medical glycerine
Add in 87.5 parts of sterile salines and be sufficiently mixed, obtain uniform mixed solution；
2nd, the mixed solution obtained 1 is degerming through 0.22 μm of filter membrane, by specification requirement potting in aseptic plastic bottle, is
Laminin surface of a wound maintenance agent product.Detected by the requirement of pharmacopeia sterile detection method, product should be sterile.
It is sprayed directly into when the 3rd, applying and handles clean wound.
Embodiment 3：
For the powder formulation of the present invention
1st, by through examining 20 parts qualified of animal blood plasma laminin sediment, 1 part of bactericide, sterile saline 79
Part mixing, it is degerming with 0.22 μm of filter membrane.It is freeze-dried that pulvis is made.Aseptic packaging, examined by the requirement of pharmacopeia sterile detection method
Survey, product should be sterile.
It can be sprayed to directly by pulvis or with normal saline dilution when the 2, applying and handle clean wound.
The product of the present invention is tested by clinic application, obtains good result.Detected through professional inspection mechanism, its physical and chemical index
And toxicity test, meet hygienic requirements, for surface applications, laminin, laminin composition or other
Therapeutic medicament can be formed in creme, washing lotion, ointment, solution or suspension in suitable water-based or non-aqueous carrier.
Claims (3)
- A kind of 1. laminin surface of a wound maintenance agent, it is characterised in that：It is based on animal blood plasma laminin sediment Composition is wanted, is formed added with sterile saline and pharmaceutic adjuvant.Its specific Parts by Ingredients, which matches, is：Animal blood pulp layer adhesion Albumen precipitation thing 1-30 parts, NMF 1-20 parts, bactericide 0.01-3.0 parts, sterile saline, complement to 100 parts.
- 2. laminin surface of a wound maintenance agent according to claim 1, it is characterised in that：The bactericide is chlorine dioxide Or chlorine dioxide precursor, wherein chlorine dioxide precursor is sodium chlorite, potassium chlorite, lithium chlorite, magnesium chlorite, barium chlorite In one or more；Emollient is medical glycerine or vegetable oil.
- 3. laminin surface of a wound maintenance agent according to claim 1, it is characterised in that：Described NMF is medical sweet One kind in the vegetable oil such as oil or coconut oil, cottonseed oil, peanut oil, sesame oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610472087.1A CN107537023A (en) | 2016-06-27 | 2016-06-27 | A kind of laminin surface of a wound maintenance agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610472087.1A CN107537023A (en) | 2016-06-27 | 2016-06-27 | A kind of laminin surface of a wound maintenance agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107537023A true CN107537023A (en) | 2018-01-05 |
Family
ID=60960822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610472087.1A Pending CN107537023A (en) | 2016-06-27 | 2016-06-27 | A kind of laminin surface of a wound maintenance agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107537023A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101873854A (en) * | 2007-10-09 | 2010-10-27 | 内华达高等教育系统董事会,代表内华达大学雷诺校区 | Laminin, derivant and comprise their compositions and their therapeutic application process |
| US20110236974A1 (en) * | 2007-05-04 | 2011-09-29 | University Of Virginia Patent Foundation | Compositions and methods for making and using laminin nanofibers |
-
2016
- 2016-06-27 CN CN201610472087.1A patent/CN107537023A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110236974A1 (en) * | 2007-05-04 | 2011-09-29 | University Of Virginia Patent Foundation | Compositions and methods for making and using laminin nanofibers |
| CN101873854A (en) * | 2007-10-09 | 2010-10-27 | 内华达高等教育系统董事会,代表内华达大学雷诺校区 | Laminin, derivant and comprise their compositions and their therapeutic application process |
Non-Patent Citations (1)
| Title |
|---|
| SEUNG-KI MIN: "The effect of a laminin-5-derived peptide coated onto chitin microfibers on re-epithelialization in early-stage wound healing", 《BIOMATERIALS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1526867B1 (en) | Erythropoietin in subpolycythemic doses | |
| CN102973982B (en) | Biomedical material applied to soft and hard tissue repair and regeneration | |
| DE69727595T2 (en) | METHOD FOR PRODUCING AN EXTRACT OF THE PLATE GROWTH FACTOR FOR PREPARATIONS FOR Wound Healing | |
| KR102578135B1 (en) | Extended release of neuregulin for treating heart failure | |
| CN108586575B (en) | Polypeptide and application of polypeptide in skin repair function | |
| KR20120092494A (en) | Degradation-stabilised, biocompatible collagen matrices | |
| US9402881B2 (en) | Tissue regeneration and wound treatment methods with platelet derived compositions | |
| CN109276705B (en) | Compositions and methods for treating heart failure in diabetics | |
| CN103948575A (en) | Application of cinnamyl aldehyde in preparing medicament for promoting angiogenesis | |
| DE60207043T2 (en) | HISTIDINE-rich GLYCOPROTEIN (HRGP) FOR INHIBITING ANGIOGENESIS | |
| EP3145533B1 (en) | Compositions for promoting the healing of wounds | |
| BR112017007645B1 (en) | COMPOSITIONS TO TREAT WOUNDS | |
| CN108324926A (en) | The composition and application thereof of stem cell extract and antibacterial peptide | |
| WO2016130931A2 (en) | Formulations of angiotensin receptor blockers | |
| CN107537023A (en) | A kind of laminin surface of a wound maintenance agent | |
| Banu et al. | Evaluation of bone marrow-derived mesenchymal stem cells with eggshell membrane for full-thickness wound healing in a rabbit model | |
| JP2002226395A (en) | Agent for promoting cure of skin wound | |
| CN100522257C (en) | Fibronectin cicatrisation agent for wounds and ulcers | |
| CN106562953A (en) | Application of hydroxysafflor yellow A in preparing medicine for treating diabetic foot ulceration, medicine and medicine preparation method | |
| RU2527701C1 (en) | Method for preparing agent possessing property of cartilaginous, osseous, muscular tissue regeneration stimulation, and method for cartilaginous, osseous, muscular tissue regeneration stimulation with using prepared agent | |
| Lozano et al. | Efficacy of an oral collagen therapy compared with intra-articular therapies (hyaluronic acid and platelet-rich plasma) to treat knee osteoarthritis. | |
| CN107296954A (en) | A kind of laminin Wound surface protection film | |
| CN111000974B (en) | Rabbit milk active small peptide solution and extraction method and application thereof | |
| CN112675294B (en) | Preparation of fibroblast and application of fibroblast in plastic surgery repair | |
| CN113069534B (en) | Application of IGSF10 in preparation of bone tissue regeneration product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180105 |